AgingResearch.NewsJoin free

Carnyx Therapeutics

CompanyUnited States

Carnyx Therapeutics develops 2 assets, the furthest preclinical (CNYX-001 in retinitis pigmentosa). Mostly other; based in the United States.

2
Assets
Furthest stage
Preclinical
0
Trials
0
Signals

Pipeline

2

  • CNYX-001

    Preclinical, Other, retinitis pigmentosa

  • CNYX-005

    Increases total sleep time and non-rapid eye movement sleep in preclinical studies.

    Preclinical, Other, sleep disorders

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Similar companies6

Intelligence